{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:39:18Z","timestamp":1767145158124,"version":"build-2238731810"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007292","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clml.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:36:39Z","timestamp":1580124999000},"page":"e304-e315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center"],"prefix":"10.1016","volume":"20","author":[{"given":"Xuelin","family":"Dou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.009_bib2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.009_bib4","first-page":"559","article-title":"A\u00a0survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients\u2019 perspective","volume":"37","author":"Jiang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1007\/s00432-017-2517-0","article-title":"Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia","volume":"143","author":"Jiang","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155214522143","article-title":"Clinical efficacy of generic imatinib","volume":"21","author":"de Lemos","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2020.01.009_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2018-99-113718","article-title":"Efficacy and safety of generic imatinib compared to glivec in chronic phase - chronic myeloid leukemia - a multicenter, observational study","volume":"132","author":"Pagnano","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.009_bib8","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/blood-2018-99-115208","article-title":"Effects of the switch to generic imatinib in a cohort of 109 Italian CML patients - the gims study","volume":"132","author":"Gemelli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2014.893302","article-title":"Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety","volume":"55","author":"Saavedra","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000319150","article-title":"Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report","volume":"3","author":"Chouffai","year":"2010","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clml.2020.01.009_bib11","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clml.2017.08.001","article-title":"Generic imatinib therapy among Jordanians: an observational assessment of efficacy and safety in routine clinical practice","volume":"17","author":"Awidi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.01.009_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1309\/LMR1KA61JYKUXRDX","article-title":"Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia","volume":"41","author":"Razmkhah","year":"2010","journal-title":"Lab Med"},{"key":"10.1016\/j.clml.2020.01.009_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12185-009-0431-1","article-title":"Failure of copy imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase","volume":"91","author":"Mattar","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.01.009_bib14","doi-asserted-by":"crossref","first-page":"9342","DOI":"10.1186\/1757-1626-2-9342","article-title":"Changing therapy from Glivecto a \u201ccopy\u201d imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports","volume":"2","author":"Asfour","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.clml.2020.01.009_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.12845","article-title":"The impact of socioeconomic factors on treatment choice and mortality in chronic myeloid leukaemia","volume":"98","author":"Larfors","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.01.009_bib16","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","article-title":"Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort","volume":"4","author":"Smith","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.clml.2020.01.009_bib17","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2013-11-539742","article-title":"The impact of health care settings on survival time of patients with chronic myeloid leukemia","volume":"123","author":"Lauseker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.009_bib18","first-page":"227","article-title":"Myeloid leukaemia treatment and survival--the South Australian experience, 1977 to 2002","volume":"7","author":"Luke","year":"2006","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2020.01.009_bib19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.01.009_bib20","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.3109\/10428194.2014.921299","article-title":"Generic imatinib: the real-deal or just a deal?","volume":"55","author":"Mathews","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.01.009_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2018.09.018","article-title":"Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy","volume":"74","author":"Bonifacio","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.01.009_bib22","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1002\/cam4.2545","article-title":"Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States","volume":"8","author":"Abou Dalle","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2020.01.009_bib23","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1182\/blood.V128.22.5451.5451","article-title":"The comparison of efficacy between generic and branded imatinib in achievement of overall survival and cytogenetic responses in CML patients in Bosnia and Herzegovina","volume":"128","author":"Kozaric","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.009_bib24","doi-asserted-by":"crossref","first-page":"e2017062","DOI":"10.4084\/mjhid.2017.062","article-title":"Outcome of frontline treatment with \u201cgeneric\u201d imatinib in adult patients with chronic myeloid leukemia in Algerian population: a multicenter study","volume":"9","author":"Entasoltan","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2020.01.009_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.critrevonc.2012.08.007","article-title":"Socio-economic inequalities: a review of methodological issues and the relationships with cancer survival","volume":"85","author":"Quaglia","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2020.01.009_bib26","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1200\/jco.2011.29.15_suppl.6004","article-title":"The impact of socioeconomic status on cancer care and survival","volume":"29","author":"Wong","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.009_bib27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.23567","article-title":"The impact of socioeconomic status on survival after cancer in the United States: findings from the national program of cancer registries patterns of care study","volume":"113","author":"Byers","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.01.009_bib28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00432-016-2158-8","article-title":"Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China","volume":"142","author":"Jiang","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2020.01.009_bib29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.01.009_bib30","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.25628","article-title":"Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin","volume":"94","author":"Lauseker","year":"2019","journal-title":"Am J Hematol"}],"updated-by":[{"DOI":"10.1016\/j.clml.2020.10.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000}}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:26Z","timestamp":1761870866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S215226502030046X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}